Following US approval last month, soon-to-be Takeda Pharmaceutical (TYO: 4502) acquisition Shire (LSE: SHP) has now also been granted authorization in Canada for Takhzyro (lanadelumab), as a treatment for hereditary angioedema (HAE).
The approval means the therapy may now be marketed for routine prevention of attacks of the rare and debilitating genetic disorder in adolescents and adults.
Takhzyro is a fully- human monoclonal antibody, given through injection. Patients can self-administer the therapy every two or four weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze